Get to know our clinical trials
Trial of venetoclax in combination with polatuzumab vedotin plus rituximab (r) and cyclophosphamide, doxorubicin and prednisone (chp) in patients with diffuse large b lymphocyte lymphoma.
THE PURPOSE OF THE STUDY IS TO TEST TWO DIFFERENT DOSING SCHEDULES OF VENETOCLAX . 800 MG VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN AND R-CHP FOR 5 DAYS AND 800 MG VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN AND R-CHP FOR 10 DAYS . TO DETERMINE IF THE COMBINATION OF THE STUDY DRUGS (ALSO CALLED THE STUDY TREATMENT) IS TOLERATED AND TO UNDERSTAND HOW YOUR BODY PROCESSES THE STUDY TREATMENT. THE DOSE AND DOSING SCHEDULE OF POLATUZUMAB VEDOTIN AND R-CHP WILL ALWAYS BE THE SAME.
- Code EudraCT: 2020-002376-12
- Protocol number: BO42203
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.